Search

Search Constraints

You searched for: Author/Creator Zeller, Cordula

Search Results

3. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Issue 4 (26th January 2021)

4. Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study. Issue 4 (December 2015)

5. Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. (14th December 2020)

6. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME. (11th September 2020)

7. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. (8th December 2021)

8. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. (22nd December 2020)

9. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Issue 4 (26th January 2021)

10. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Issue 16 (19th October 2021)